Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence: Weight change after T2D medications
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aims The study aims to examine real-world weight change and the role of medication adherence among patients with type 2 diabetes who initiated one of three drug classes: glucagon-like peptide-1 receptor agonist (GLP-1RA), dipeptidyl peptidase-4 inhibitor (DPP4) and sulfonylureas (SUs). Materials and methods A cohort of patients initiating one of the three drug classes was selected from a large US database of integrated electronic medical record and administrative claims. Adherence was defined as per cent of days covered ≥80% during the year following drug initiation. Weight change was calculated from drug initiation (−180, +30 d) to 1 year (±90 d) later. Multivariate regression controlled for baseline differences between adherent and poorly adherent patients and the addition of another drug class during follow-up. Results The study included 833 GLP-1RA, 2,272 DPP4 and 2,713 SU patients who contributed 2,279, 6,602 and 7,429 observations respectively. Patients initiating a GLP-1RA achieved the largest weight change (−2.46 kg of GLP-1RA, −1.26 kg of DPP4 and 0.18 kg of SU, P < 0.01). Adherent GLP-1 patients lost 1.73 kg more than poorly adherent patients, and adherent SU patients gained 1.11 kg more than poorly adherent patients (all P < 0.01). Adherent and poorly adherent DPP4 patients experienced approximately the same amount of weight loss. Conclusions Medication adherence can mediate observed weight loss in patients treated with a GLP1-RA or weight gain in those treated with an SU. Medication adherence was low in a real-world population, particularly for GLP-1RA, which displayed the strongest weight loss benefit. Because recent American Diabetes Association guidelines recommend selecting drug therapies that have a weight loss or weight neutral effect for the management of type 2 diabetes patients, patients should be encouraged to enhance their adherence to benefit the most from therapies that have weight loss properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“52) Baseline patient characteristics Age, mean (SD) 56 (10) 62 (12) 63 (14) Age, % (N) Under 45 14 (116) 9 (205) 9 (232) 45–64 63 (526) 46 (1,054) 43 (1,165) 65 and older 23 (191) 45 (1,013) 49 (1,316) Sex, % male (N) 47 (392) 54 (1,236) 55 (1,495) Race, % white (N) 83 (693) 79 (1,799) 80 (2,167) Weight, kg, mean (SD)…”
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522
Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“Consistent with evidence from clinical trials, this study demonstrated that GLP-1RA treatment is associated with weight loss, SU treatment is associated with weight gain, and DPP4 treatment is weight neutral in real-world patients (11,12).”
ResultEight-year weight losses with an intensive lifestyle intervention: The look AHEAD study
The Look AHEAD Research Group (2014) · Obesity · doi:10.1002/oby.20662 · Cited by 842
Comparative Effectiveness of Weight-Loss Interventions in Clinical Practice
Appel, L. J., Clark, J. M., Yeh, H.-C., Wang, N.-Y., Coughlin, J. W., Daumit, G., Miller, E. R., Dalcin, A., Jerome, G. J., Geller, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108660 · Cited by 783
A Two-Year Randomized Trial of Obesity Treatment in Primary Care Practice
Wadden, T. A., Volger, S., Sarwer, D. B., Vetter, M. L., Tsai, A. G., Berkowitz, R. I., Kumanyika, S., Schmitz, K. H., Diewald, L. K., Barg, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109220 · Cited by 487
A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes
Asche, C., LaFleur, J., & Conner, C. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.01.019 · Cited by 420
The importance of weight management in type 2 diabetes mellitus
Wilding, J. P. H. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12384 · Cited by 314 · cited 1×
“52) Baseline patient characteristics Age, mean (SD) 56 (10) 62 (12) 63 (14) Age, % (N) Under 45 14 (116) 9 (205) 9 (232) 45–64 63 (526) 46 (1,054) 43 (1,165) 65 and older 23 (191) 45 (1,013) 49 (1,316) Sex, % male (N) 47 (392) 54 (1,236) 55 (1,495) Race, % white (N) 83 (693) 79 (1,799) 80 (2,167) Weight, kg, mean (SD)…”
Singh, S., Wright, E. E., Kwan, A. Y. M., Thompson, J. C., Syed, I. A., Korol, E. E., Waser, N. A., Yu, M. B., & Juneja, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12805 · Cited by 101
Buysman, E. K., Liu, F., Hammer, M., & Langer, J. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0199-z · Cited by 101 · cited 7×
“It has also been used in Medicare Star ratings, which measure adherence to oral antidiabetic agents as a group, rather than to a specific drug the patient has filled, which yield different estimates if the patient is taking multiple medications to treat diabetes (13,14,16,17).”
BackgroundMethodInfluential
Cited by
Guerci, B., Chanan, N., Kaur, S., Jasso-Mosqueda, J. G., & Lew, E. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0590-x · Cited by 106
Adherence and persistence rates of major antidiabetic medications: a review
Lee, D. S. U., & Lee, H. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00785-1 · Cited by 72
“Moreover, sulfonylureas amplified weight gain in the first six months of treatment [36].”
BackgroundGuerci, B., Charbonnel, B., Gourdy, P., Hadjadj, S., Hanaire, H., Marre, M., & Vergès, B. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.006 · Cited by 40
Struik, N. A., Brinkworth, G. D., Thompson, C. H., Buckley, J. D., Wittert, G., & Luscombe-Marsh, N. D. (2020) · The Journal of Nutrition · doi:10.1093/jn/nxz344 · Cited by 19
Effect of Antidepressants on Glucagon-Like Peptide-1 Receptor Agonist-Related Weight Loss
Durell, N., Franks, R., Coon, S., Cowart, K., & Carris, N. W. (2022) · Journal of Pharmacy Technology · doi:10.1177/87551225221110850 · Cited by 15
Metadata
- Authors
- Carls, G. S., Tan, R., Zhu, J. Y., Tuttle, E., Yee, J., Edelman, S. V., & Polonsky, W. H.
- Venue
- Obesity Science & Practice
- Publisher
- Wiley
- Published
- 2017-07-20
- Volume
- 3
- Issue
- 3
- Pages
- 342-351
- ISSN
- 2055-2238 (ISSN-L)
- OpenAlex
- W2620356640
- Cited by
- 29
- References
- 12
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.